Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long‐acting insulin in Type 2 diabetes¹

Abstract

Basal continuous subcutaneous infusion of a rapid-acting insulin analogue improved plasma insulin (more flat insulin profile with a lower variability) and glucose (lower AUC) profiles compared with once-daily subcutaneous injection of a long-acting insulin analogue in Type 2 diabetes.